Triple
T19773588
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Teva Pharmaceutical Industries |
E474949
|
entity |
| Predicate | notableProduct |
P1448
|
FINISHED |
| Object | Copaxone |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Copaxone | Statement: [Teva Pharmaceutical Industries, notableProduct, Copaxone]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Copaxone Context triple: [Teva Pharmaceutical Industries, notableProduct, Copaxone]
-
A.
Copaxone
chosen
Copaxone is a disease-modifying immunotherapy drug used to treat relapsing forms of multiple sclerosis by reducing the frequency of flare-ups.
-
B.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
C.
Tecfidera
Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
-
D.
fingolimod
Fingolimod is an oral disease-modifying immunomodulatory drug used to reduce relapses and delay disability progression in people with relapsing forms of multiple sclerosis.
-
E.
Rinvoq
Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8e51a43a08190956bc6df13c91a77 |
completed | April 10, 2026, 11:55 a.m. |
| NER | Named-entity recognition | batch_69e6535e450c8190a2628245ae0d0bd3 |
completed | April 20, 2026, 4:25 p.m. |
Created at: April 10, 2026, 1:48 p.m.